These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16537407)

  • 1. Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.
    Zarandi M; Varga JL; Schally AV; Horvath JE; Toller GL; Kovacs M; Letsch M; Groot K; Armatis P; Halmos G
    Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4610-5. PubMed ID: 16537407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
    Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
    Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.
    Varga JL; Schally AV; Csernus VJ; Zarándi M; Halmos G; Groot K; Rékási Z
    Proc Natl Acad Sci U S A; 1999 Jan; 96(2):692-7. PubMed ID: 9892695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
    Rekasi Z; Varga JL; Schally AV; Halmos G; Armatis P; Groot K; Czompoly T
    Endocrinology; 2000 Jun; 141(6):2120-8. PubMed ID: 10830299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.
    Varga JL; Schally AV; Horvath JE; Kovacs M; Halmos G; Groot K; Toller GL; Rekasi Z; Zarandi M
    Proc Natl Acad Sci U S A; 2004 Feb; 101(6):1708-13. PubMed ID: 14755056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action.
    Kovacs M; Zarándi M; Halmos G; Groot K; Schally AV
    Endocrinology; 1996 Dec; 137(12):5364-9. PubMed ID: 8940358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
    Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
    Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.
    Rekasi Z; Varga JL; Schally AV; Halmos G; Groot K; Czompoly T
    Proc Natl Acad Sci U S A; 2000 Feb; 97(3):1218-23. PubMed ID: 10655511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
    Plonowski A; Schally AV; Varga JL; Rekasi Z; Hebert F; Halmos G; Groot K
    Prostate; 2000 Jul; 44(2):172-80. PubMed ID: 10881027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
    Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Busto R; Halmos G
    J Clin Endocrinol Metab; 2001 May; 86(5):2144-52. PubMed ID: 11344219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone.
    Zarandi M; Horvath JE; Halmos G; Pinski J; Nagy A; Groot K; Rekasi Z; Schally AV
    Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12298-302. PubMed ID: 7991622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
    Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
    Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly.
    Kovacs M; Kineman RD; Schally AV; Zarandi M; Groot K; Frohman LA
    Endocrinology; 1997 Nov; 138(11):4536-42. PubMed ID: 9348175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH.
    Schally AV; Wang H; He J; Cai R; Sha W; Popovics P; Perez R; Vidaurre I; Zhang X
    Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12028-12033. PubMed ID: 30373845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of long-acting antagonists of growth hormone (GH)-releasing hormone on GH and cyclic adenosine 3',5'-monophosphate release in superfused rat pituitary cells.
    Horváth JE; Zarándi M; Groot K; Schally AV
    Endocrinology; 1995 Sep; 136(9):3849-55. PubMed ID: 7649091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
    Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
    Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
    Engel JB; Keller G; Schally AV; Toller GL; Groot K; Havt A; Armatis P; Zarandi M; Varga JL; Halmos G
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3614-21. PubMed ID: 15784701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
    Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
    Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.
    Kahán Z; Varga JL; Schally AV; Rékási Z; Armatis P; Chatzistamou L; Czömpöly T; Halmos G
    Breast Cancer Res Treat; 2000 Mar; 60(1):71-9. PubMed ID: 10845811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.